<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02169713</url>
  </required_header>
  <id_info>
    <org_study_id>178-CL-109</org_study_id>
    <secondary_id>2013-004230-15</secondary_id>
    <nct_id>NCT02169713</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Effect of Steady State Solifenacin and Mirabegron on the Steady State Pharmacokinetics of Tamsulosin HCl in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of solifenacin and mirabegron on the&#xD;
      concentrations of tamsulosin HCl after combined dosing. This study will also evaluate the&#xD;
      safety and tolerability of the combined administration of solifenacin, mirabegron and&#xD;
      tamsulosin HCl.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is comprised of two study sequences with 2 investigational periods in each&#xD;
      sequence. There will be a wash-out period between each investigational period. Patients will&#xD;
      be admitted to the clinic until discharged after each investigational period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameter for tamsulosin HCl (plasma) in the absence and presence of solifenacin and mirabegron: Cmax</measure>
    <time_frame>Day 14 in each investigational period</time_frame>
    <description>Maximum concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter for tamsulosin HCl (plasma) in the absence and presence of solifenacin and mirabegron: AUCtau</measure>
    <time_frame>Day 14 in each investigational period</time_frame>
    <description>Area under the curve over a dosing interval (AUCtau)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter for tamsulosin HCl (plasma): Ctrough</measure>
    <time_frame>Days 11, 12 and 13 in each investigational period</time_frame>
    <description>Concentration immediately prior to dosing at multiple dosing (Ctrough)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter for tamsulosin HCl (plasma): tmax, CL/F, PTR</measure>
    <time_frame>Day 14 in each investigational period</time_frame>
    <description>Time after dosing when Cmax occurs (tmax), apparent total systemic clearance after single or multiple extra-vascular dosing (CL/F), Peak-through ratio (PTR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter for solifenacin and mirabegron (plasma): Ctrough</measure>
    <time_frame>Days 11, 12 and 13 in each investigational period</time_frame>
    <description>Concentration immediately prior to dosing at multiple dosing (Ctrough)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter for solifenacin and mirabegron (plasma): Cmax, AUCtau, tmax, CL/F</measure>
    <time_frame>Day 14 in each investigational period</time_frame>
    <description>Maximum concentration (Cmax), Area under the curve over a dosing interval (AUCtau), Time after dosing when Cmax occurs (tmax), apparent total systemic clearance after single or multiple extra-vascular dosing (CL/F)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy Subjects</condition>
  <condition>Pharmacokinetics</condition>
  <condition>Drug-Drug Interaction (DDI)</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tamsulosin HCl alone (with matching placebo for solifenacin and mirabegron) then followed by tamsulosin HCl with solifenacin and mirabegron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tamsulosin HCl with solifenacin and mirabegron then followed by tamsulosin HCl alone (with matching placebo for solifenacin and mirabegron)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirabegron</intervention_name>
    <description>Oral</description>
    <arm_group_label>Treatment Sequence 1</arm_group_label>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
    <other_name>Myrbetriq</other_name>
    <other_name>Betmiga</other_name>
    <other_name>Betanis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin succinate</intervention_name>
    <description>Oral</description>
    <arm_group_label>Treatment Sequence 1</arm_group_label>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
    <other_name>solifenacin</other_name>
    <other_name>Vesikur</other_name>
    <other_name>Vesicare</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin HCl</intervention_name>
    <description>Oral</description>
    <arm_group_label>Treatment Sequence 1</arm_group_label>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
    <other_name>Flomax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
    <arm_group_label>Treatment Sequence 1</arm_group_label>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has a body mass index range of 18.5 to 30.0 kg/m2, inclusive. The subject&#xD;
             weighs at least 50 kg [screening].&#xD;
&#xD;
          -  Subject and their female spouse/partners who are of childbearing potential must be&#xD;
             using a highly effective form of contraception consisting of 2 forms of birth control&#xD;
             (one of which must be a barrier method) starting at screening and continue throughout&#xD;
             the clinical study period and for 90 days after the final study drug administration.&#xD;
&#xD;
          -  Subject must not donate sperm starting at screening and throughout the clinical study&#xD;
             period and for 90 days after the final study drug administration.&#xD;
&#xD;
          -  Subject agrees not to participate in another interventional study while participation&#xD;
             in the present clinical study, defined as signing the informed consent form until&#xD;
             completion of the last clinical study visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a known or suspected hypersensitivity to solifenacin succinate,&#xD;
             mirabegron, tamsulosin HCl or any components of the formulations used including sulfa&#xD;
             allergies.&#xD;
&#xD;
          -  Subject has any of the liver function tests (aspartate aminotransferase [AST], alanine&#xD;
             aminotransferase [ALT], alkaline phosphatase, gamma-glutamyl transferase and/or total&#xD;
             bilirubin [TBL]) above 1.5 of the upper limit of normal (ULN). In such a case the&#xD;
             assessment may be repeated once [day-1].&#xD;
&#xD;
          -  Subject has any clinically significant history of allergic conditions.&#xD;
&#xD;
          -  Subject has any history or evidence of any clinically significant cardiovascular,&#xD;
             gastrointestinal, endocrine, hematologic, hepatic, immunologic, metabolic, urologic,&#xD;
             pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease or&#xD;
             malignancy, as judged by the Medical Investigator.&#xD;
&#xD;
          -  Subject has/had febrile illness or symptomatic, viral, bacterial (including upper&#xD;
             respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to day&#xD;
             -2 (admission day).&#xD;
&#xD;
          -  Subject has any clinically significant abnormality following the Investigator's review&#xD;
             of the physical examination, electrocardiogram (ECG) and protocol-defined clinical&#xD;
             laboratory tests at screening or day -1.&#xD;
&#xD;
          -  Subject has a mean pulse rate of &lt; 50 or &gt; 90 bpm; mean systolic BP &lt; 90 mmHg or &gt; 140&#xD;
             mmHg; mean diastolic BP &lt; 60 mmHg or &gt; 90 mmHg at day -1 (vital sign measurements&#xD;
             taken in triplicate after subject has been resting in supine position for 10 min;&#xD;
             pulse rate will be measured automatically).&#xD;
&#xD;
          -  Subject has a mean QTc(F) interval of &gt; 430 ms (&gt; 450 for subjects aged 65 and above)&#xD;
             at day -1. If the mean QTc(F) exceeds the limits above, 1 additional triplicate ECG&#xD;
             can be taken.&#xD;
&#xD;
          -  Subject has any clinical significant history of or risk of urinary retention, severe&#xD;
             gastrointestinal condition (including toxic megacolon), myasthenia gravis or&#xD;
             narrow-angle glaucoma, orthostatic hypotension.&#xD;
&#xD;
          -  Subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac&#xD;
             arrhythmias or torsade de pointes, structural heart disease, or a family history of&#xD;
             Long QT Syndrome.&#xD;
&#xD;
          -  Subject uses any prescribed or non-prescribed drugs (including vitamins, natural and&#xD;
             herbal remedies [e.g., St. John's Wort]) in the 2 weeks prior to study drug&#xD;
             administration, except for occasional use of paracetamol (up to 2 g/day).&#xD;
&#xD;
          -  Subject has a history of smoking more than 10 cigarettes (or equivalent amount of&#xD;
             tobacco) per day within 3 months prior to admission to the clinical unit on day -2.&#xD;
&#xD;
          -  Subject has a history of drinking more than 21 units of alcohol per week (1 unit = 10&#xD;
             g pure alcohol = 250 mL of beer [5%] or 35 mL of spirits [35%] or 100 mL of wine&#xD;
             [12%]) within 3 months prior to admission to the clinical unit on day -2.&#xD;
&#xD;
          -  Subject has consumed grapefruit (more than 3 x 200 mL) or marmalade (more than 3&#xD;
             times), star fruit, Seville oranges or Seville orange juice-containing products in the&#xD;
             week prior to admission to the clinical unit until end of study visit (ESV), as&#xD;
             reported by the subject.&#xD;
&#xD;
          -  Subject uses any drugs of abuse within 3 months prior to admission to the clinical&#xD;
             unit.&#xD;
&#xD;
          -  Subject uses any inducer of metabolism (e.g., barbiturates, rifampin) in the 3 months&#xD;
             prior to admission to the clinical unit regularly.&#xD;
&#xD;
          -  Subject has significant blood loss, donated 1 unit (500 mL) of blood or more, or&#xD;
             received a transfusion of any blood or blood products within 60 days or donated plasma&#xD;
             within 7 days prior to clinical unit admission on day -2.&#xD;
&#xD;
          -  Subject has a positive serology test for hepatitis B surface antigen, hepatitis B core&#xD;
             antibodies, hepatitis A virus antibodies (Immunoglobulin M), hepatitis C virus&#xD;
             antibodies or human immunodeficiency virus 1 + 2 antibodies.&#xD;
&#xD;
          -  Subject participated in any clinical study or has been treated with any&#xD;
             investigational drugs within 28 days prior to screening.&#xD;
&#xD;
          -  Subject is a vulnerable subject (e.g., subject kept in detention).&#xD;
&#xD;
          -  Subject is an employee of the Astellas Group or Contract Research Organization&#xD;
             involved in the clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Research Physician</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel International GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>June 5, 2014</study_first_submitted>
  <study_first_submitted_qc>June 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <last_update_submitted>August 27, 2014</last_update_submitted>
  <last_update_submitted_qc>August 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy subjects</keyword>
  <keyword>Mirabegron</keyword>
  <keyword>Solifenacin</keyword>
  <keyword>Tamsulosin HCl</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Solifenacin Succinate</mesh_term>
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

